IL209548A - Diazacarbols and Methods of Use - Google Patents

Diazacarbols and Methods of Use

Info

Publication number
IL209548A
IL209548A IL209548A IL20954810A IL209548A IL 209548 A IL209548 A IL 209548A IL 209548 A IL209548 A IL 209548A IL 20954810 A IL20954810 A IL 20954810A IL 209548 A IL209548 A IL 209548A
Authority
IL
Israel
Prior art keywords
alkyl
groups
compound
heterocyclyl
optionally substituted
Prior art date
Application number
IL209548A
Other languages
English (en)
Hebrew (he)
Other versions
IL209548A0 (en
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of IL209548A0 publication Critical patent/IL209548A0/en
Publication of IL209548A publication Critical patent/IL209548A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL209548A 2008-06-11 2010-11-24 Diazacarbols and Methods of Use IL209548A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US6075008P 2008-06-11 2008-06-11
US14800409P 2009-01-28 2009-01-28
PCT/US2009/003481 WO2009151589A1 (en) 2008-06-11 2009-06-10 Diazacarbazoles and methods of use

Publications (2)

Publication Number Publication Date
IL209548A0 IL209548A0 (en) 2011-01-31
IL209548A true IL209548A (en) 2014-03-31

Family

ID=41066268

Family Applications (1)

Application Number Title Priority Date Filing Date
IL209548A IL209548A (en) 2008-06-11 2010-11-24 Diazacarbols and Methods of Use

Country Status (12)

Country Link
US (1) US20110124654A1 (enExample)
EP (1) EP2324024B1 (enExample)
JP (2) JP5677945B2 (enExample)
KR (2) KR20110015699A (enExample)
CN (1) CN102119162B (enExample)
AU (1) AU2009258115B2 (enExample)
BR (1) BRPI0909957A2 (enExample)
CA (1) CA2726114A1 (enExample)
ES (1) ES2392489T3 (enExample)
IL (1) IL209548A (enExample)
MX (1) MX2010013606A (enExample)
WO (1) WO2009151589A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2726114A1 (en) * 2008-06-11 2009-12-17 Genentech, Inc. Diazacarbazoles and methods of use
CN108721284A (zh) 2010-11-16 2018-11-02 阵列生物制药公司 检测点激酶1抑制剂和wee1激酶抑制剂的组合
GB201201566D0 (en) 2012-01-30 2012-03-14 Vernalis R&D Ltd New chemical compounds
RU2635359C2 (ru) * 2012-04-23 2017-11-13 Дженентек Инк. Промежуточные химические соединения и способы получения соединений
EP2948438A4 (en) * 2013-01-23 2016-10-05 Univ Chicago METHOD AND COMPOSITIONS FOR INHIBITING THE HUMAN COPPER TRAFFICKING PROTEIN ATOX1 AND CCS
AU2014293013A1 (en) 2013-07-26 2016-03-17 Race Oncology Ltd. Combinatorial methods to improve the therapeutic benefit of bisantrene
AU2014333996B2 (en) 2013-10-08 2018-03-15 F. Hoffmann-La Roche Ag Diazacarbazole derivatives as tau-pet-ligands
JP6840931B2 (ja) * 2015-03-09 2021-03-10 東ソー株式会社 縮環芳香族化合物の製造方法
US20170067946A1 (en) * 2015-06-08 2017-03-09 Zac WHEELER Monitoring system with low power usage
CN109789143A (zh) 2016-07-01 2019-05-21 G1治疗公司 基于嘧啶的抗增殖剂
WO2018046428A1 (en) 2016-09-09 2018-03-15 F. Hoffmann-La Roche Ag Process for preparation of 2-(6-nitropyridin-3-yl)-9h-dipyrido[2,3-b;3',4'-d]pyrrole
US11760701B2 (en) 2018-02-27 2023-09-19 The Research Foundation For The State University Of New Yrok Difluoromethoxylation and trifluoromethoxylation compositions and methods for synthesizing same
JP7853532B2 (ja) 2020-05-19 2026-04-30 ファーマコスモス ホールディング エー／エス 医学的障害を治療するためのサイクリン依存性キナーゼ阻害化合物
CN115572282B (zh) * 2021-07-05 2024-07-09 华东理工大学 含芳杂环结构的吡唑酰胺类化合物及其制备方法和应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1268477B1 (en) 2000-03-15 2010-04-21 Sanofi-Aventis Deutschland GmbH Substituted beta-carbolines with ikb-kinase inhibiting activity
CA2402549A1 (en) * 2000-03-15 2001-09-20 Aventis Pharma Deutschland Gmbh Substituted beta-carbolines
AU5261001A (en) * 2000-04-27 2001-11-12 Imperial Cancer Research Technology Ltd Condensed heteroaryl derivatives
US6608053B2 (en) * 2000-04-27 2003-08-19 Yamanouchi Pharmaceutical Co., Ltd. Fused heteroaryl derivatives
BRPI0407544A (pt) * 2003-02-17 2006-02-14 Pharmacia Italia Spa derivados de pirazol tetracìclicos como inibidores da cinase, processo para a sua preparação e composições farmacêuticas que os compreendem
AR049300A1 (es) * 2004-06-15 2006-07-12 Schering Corp Compuestos triciclicos antagonistas de mglur1 como agentes terapeuticos
US8119655B2 (en) 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
US8618121B2 (en) 2007-07-02 2013-12-31 Cancer Research Technology Limited 9H-pyrimido[4,5-B]indoles, 9H-pyrido[4',3':4,5]pyrrolo[2,3-D]pyridines, and 9H 1,3,6,9 tetraaza-fluorenes as CHK1 kinase function inhibitors
CA2726114A1 (en) * 2008-06-11 2009-12-17 Genentech, Inc. Diazacarbazoles and methods of use

Also Published As

Publication number Publication date
IL209548A0 (en) 2011-01-31
MX2010013606A (es) 2010-12-21
KR101764556B1 (ko) 2017-08-02
JP2014196309A (ja) 2014-10-16
ES2392489T3 (es) 2012-12-11
CN102119162A (zh) 2011-07-06
KR20110015699A (ko) 2011-02-16
KR20160074680A (ko) 2016-06-28
CA2726114A1 (en) 2009-12-17
BRPI0909957A2 (pt) 2016-04-19
EP2324024A1 (en) 2011-05-25
US20110124654A1 (en) 2011-05-26
AU2009258115B2 (en) 2015-01-29
CN102119162B (zh) 2014-10-08
AU2009258115A2 (en) 2011-05-12
WO2009151589A1 (en) 2009-12-17
JP2011522888A (ja) 2011-08-04
JP5677945B2 (ja) 2015-02-25
AU2009258115A1 (en) 2009-12-17
EP2324024B1 (en) 2012-09-26

Similar Documents

Publication Publication Date Title
AU2009258115B2 (en) Diazacarbazoles and methods of use
CA2725754C (en) Diazacarbazoles and methods of use
US8293763B2 (en) 8-anilinoimidazopyridines and their use as anti-cancer and/or anti-inflammatory agents
EP2164850B1 (en) N-substituted azaindoles and methods of use
US20110130406A1 (en) Pyrazolo-pyridines as tyrosine kinase inhibitors
CN109219604A (zh) 四氢异喹啉雌激素受体调节剂及其用途
EP2513110A1 (en) 1, 7 - diazacarbazoles and their use in the treatment of cancer
US20150368244A1 (en) Diazacarbazoles and methods of use
EP2300457B1 (en) Substituted pyrroles and methods of use
WO2023116594A1 (zh) 取代的稠杂环化合物及其制备方法与应用
HK1195774A (en) Diazacarbazoles and methods of use

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees